Monthly Archives: March 2019

SeaSpine Holdings (SPNE) Receives a Buy from BTIG

BTIG analyst Ryan Zimmerman reiterated a Buy rating on SeaSpine Holdings (SPNE – Research Report) on March 28 and set a price target of $20. The company’s shares closed on Friday at $15.08. Zimmerman wrote: “We reiterate our Buy rating

Sarepta Therapeutics (SRPT) Gets a Buy Rating from Cowen & Co.

Cowen & Co. analyst Ritu Baral maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on March 28 and set a price target of $213. The company’s shares closed on Friday at $119.19. According to TipRanks.com, Baral is

Cowen & Co. Believes Phasebio Pharmaceuticals Inc (NASDAQ: PHAS) Won’t Stop Here

In a report issued on March 27, Phil Nadeau from Cowen & Co. maintained a Buy rating on Phasebio Pharmaceuticals Inc (PHAS – Research Report). The company’s shares closed on Friday at $9.51, close to its 52-week high of $9.60.

Walgreens Boots Alliance (WBA) Gets a Hold Rating from Cowen & Co.

In a report issued on March 27, Charles Rhyee from Cowen & Co. maintained a Hold rating on Walgreens Boots Alliance (WBA – Research Report), with a price target of $66. The company’s shares closed on Friday at $63.27, close

Cowen & Co. Thinks Centene Corp’s Stock is Going to Recover

In a report issued on March 26, Charles Rhyee from Cowen & Co. maintained a Buy rating on Centene Corp (CNC – Research Report), with a price target of $77. The company’s shares closed on Friday at $53.10, close to

Analysts Offer Insights on Healthcare Companies: Heat Biologics (NASDAQ: HTBX), Jazz Pharmaceuticals (NASDAQ: JAZZ) and Mediwound (NASDAQ: MDWD)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Heat Biologics (HTBX – Research Report), Jazz Pharmaceuticals (JAZZ – Research Report) and Mediwound (MDWD – Research Report) with bullish sentiments. Heat